353 related articles for article (PubMed ID: 18927459)
1. Extension of the thrombolytic time window with minocycline in experimental stroke.
Murata Y; Rosell A; Scannevin RH; Rhodes KJ; Wang X; Lo EH
Stroke; 2008 Dec; 39(12):3372-7. PubMed ID: 18927459
[TBL] [Abstract][Full Text] [Related]
2. Involvement of matrix metalloproteinase in thrombolysis-associated hemorrhagic transformation after embolic focal ischemia in rats.
Sumii T; Lo EH
Stroke; 2002 Mar; 33(3):831-6. PubMed ID: 11872911
[TBL] [Abstract][Full Text] [Related]
3. Normobaric hyperoxia reduces the neurovascular complications associated with delayed tissue plasminogen activator treatment in a rat model of focal cerebral ischemia.
Liu W; Hendren J; Qin XJ; Liu KJ
Stroke; 2009 Jul; 40(7):2526-31. PubMed ID: 19478225
[TBL] [Abstract][Full Text] [Related]
4. Effects of minocycline plus tissue plasminogen activator combination therapy after focal embolic stroke in type 1 diabetic rats.
Fan X; Lo EH; Wang X
Stroke; 2013 Mar; 44(3):745-52. PubMed ID: 23422086
[TBL] [Abstract][Full Text] [Related]
5. Reduction of tissue plasminogen activator-induced hemorrhage and brain injury by free radical spin trapping after embolic focal cerebral ischemia in rats.
Asahi M; Asahi K; Wang X; Lo EH
J Cereb Blood Flow Metab; 2000 Mar; 20(3):452-7. PubMed ID: 10724108
[TBL] [Abstract][Full Text] [Related]
6. Progesterone attenuates hemorrhagic transformation after delayed tPA treatment in an experimental model of stroke in rats: involvement of the VEGF-MMP pathway.
Won S; Lee JH; Wali B; Stein DG; Sayeed I
J Cereb Blood Flow Metab; 2014 Jan; 34(1):72-80. PubMed ID: 24045404
[TBL] [Abstract][Full Text] [Related]
7. Matrix metalloproteinase-9 in an exploratory trial of intravenous minocycline for acute ischemic stroke.
Switzer JA; Hess DC; Ergul A; Waller JL; Machado LS; Portik-Dobos V; Pettigrew LC; Clark WM; Fagan SC
Stroke; 2011 Sep; 42(9):2633-5. PubMed ID: 21737808
[TBL] [Abstract][Full Text] [Related]
8. Postischemic (6-Hour) treatment with recombinant human tissue plasminogen activator and proteasome inhibitor PS-519 reduces infarction in a rat model of embolic focal cerebral ischemia.
Zhang L; Zhang ZG; Zhang RL; Lu M; Adams J; Elliott PJ; Chopp M
Stroke; 2001 Dec; 32(12):2926-31. PubMed ID: 11739997
[TBL] [Abstract][Full Text] [Related]
9. Transient brain hypothermia reduces the reperfusion injury of delayed tissue plasminogen activator and extends its therapeutic time window in a focal embolic stroke model.
Zarisfi M; Allahtavakoli F; Hassanipour M; Khaksari M; Rezazadeh H; Allahtavakoli M; Taghavi MM
Brain Res Bull; 2017 Sep; 134():85-90. PubMed ID: 28710023
[TBL] [Abstract][Full Text] [Related]
10. Combination therapy with normobaric oxygen (NBO) plus thrombolysis in experimental ischemic stroke.
Fujiwara N; Murata Y; Arai K; Egi Y; Lu J; Wu O; Singhal AB; Lo EH
BMC Neurosci; 2009 Jul; 10():79. PubMed ID: 19604385
[TBL] [Abstract][Full Text] [Related]
11. Effects of edaravone, a free radical scavenger, on circulating levels of MMP-9 and hemorrhagic transformation in patients with intravenous thrombolysis using low-dose alteplase.
Tsuruoka A; Atsumi C; Mizukami H; Imai T; Hagiwara Y; Hasegawa Y
J Stroke Cerebrovasc Dis; 2014; 23(10):2894-2899. PubMed ID: 25282183
[TBL] [Abstract][Full Text] [Related]
12. Dodecafluoropentane Emulsion Extends Window for tPA Therapy in a Rabbit Stroke Model.
Culp WC; Brown AT; Lowery JD; Arthur MC; Roberson PK; Skinner RD
Mol Neurobiol; 2015 Oct; 52(2):979-84. PubMed ID: 26055229
[TBL] [Abstract][Full Text] [Related]
13. Blood-brain barrier disruption and matrix metalloproteinase-9 expression during reperfusion injury: mechanical versus embolic focal ischemia in spontaneously hypertensive rats.
Aoki T; Sumii T; Mori T; Wang X; Lo EH
Stroke; 2002 Nov; 33(11):2711-7. PubMed ID: 12411666
[TBL] [Abstract][Full Text] [Related]
14. A Rho kinase (ROCK) inhibitor, fasudil, prevents matrix metalloproteinase-9-related hemorrhagic transformation in mice treated with tissue plasminogen activator.
Ishiguro M; Kawasaki K; Suzuki Y; Ishizuka F; Mishiro K; Egashira Y; Ikegaki I; Tsuruma K; Shimazawa M; Yoshimura S; Iwama T; Hara H
Neuroscience; 2012 Sep; 220():302-12. PubMed ID: 22710066
[TBL] [Abstract][Full Text] [Related]
15. Repurposing an old drug to improve the use and safety of tissue plasminogen activator for acute ischemic stroke: minocycline.
Hess DC; Fagan SC
Pharmacotherapy; 2010 Jul; 30(7 Pt 2):55S-61S. PubMed ID: 20575623
[TBL] [Abstract][Full Text] [Related]
16. Whole body hypothermia extends tissue plasminogen activator treatment window in the rat model of embolic stroke.
Hassanipour M; Zarisfi M; Ehsani V; Allahtavakoli M
Life Sci; 2020 Sep; 256():117450. PubMed ID: 32087233
[TBL] [Abstract][Full Text] [Related]
17. Normobaric hyperoxia slows blood-brain barrier damage and expands the therapeutic time window for tissue-type plasminogen activator treatment in cerebral ischemia.
Liang J; Qi Z; Liu W; Wang P; Shi W; Dong W; Ji X; Luo Y; Liu KJ
Stroke; 2015 May; 46(5):1344-1351. PubMed ID: 25804925
[TBL] [Abstract][Full Text] [Related]
18. Toll-Like Receptor 4 Mediates Hemorrhagic Transformation After Delayed Tissue Plasminogen Activator Administration in In Situ Thromboembolic Stroke.
García-Culebras A; Palma-Tortosa S; Moraga A; García-Yébenes I; Durán-Laforet V; Cuartero MI; de la Parra J; Barrios-Muñoz AL; Díaz-Guzmán J; Pradillo JM; Moro MA; Lizasoain I
Stroke; 2017 Jun; 48(6):1695-1699. PubMed ID: 28428349
[TBL] [Abstract][Full Text] [Related]
19. Usefulness of postischemic thrombolysis with or without neuroprotection in a focal embolic model of cerebral ischemia.
Yang Y; Li Q; Miyashita H; Howlett W; Siddiqui M; Shuaib A
J Neurosurg; 2000 May; 92(5):841-7. PubMed ID: 10794299
[TBL] [Abstract][Full Text] [Related]
20. Impact of the neutrophil response to granulocyte colony-stimulating factor on the risk of hemorrhage when used in combination with tissue plasminogen activator during the acute phase of experimental stroke.
Gautier S; Ouk T; Tagzirt M; Lefebvre C; Laprais M; Pétrault O; Dupont A; Leys D; Bordet R
J Neuroinflammation; 2014 May; 11():96. PubMed ID: 24885160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
